Patent Publication Number: US-9414760-B2

Title: Method for monitoring physiological cycles of a patient to optimize patient therapy

Description:
RELATED APPLICATIONS 
     This application is a divisional of U.S. patent application Ser. No. 13/538,571, filed Jun. 29, 2012, which is a continuation of U.S. patent application Ser. No. 12/347,813, filed Dec. 31, 2008 and now issued as U.S. Pat. No. 8,214,050, which claims the benefit of Provisional Patent Application No. 61/018,195, filed Dec. 31, 2007, the disclosures of which are hereby incorporated by reference. 
    
    
     FIELD OF THE INVENTION 
     The present invention relates generally to methods for monitoring physiological activity of a patient with an implantable device. More particularly, the present invention relates to detection of physiological parameters of a patient along at least three vectors, which can then be used to optimize patient therapy. 
     BACKGROUND OF THE INVENTION 
     Electrocardiograms (ECG or EKG) are commonly used to monitor and diagnose heart conditions. An ECG is a recording made by an electrocardiograph of electric waves generated during activity in the heart. To measure an ECG, electrodes, or electrical contacts, are placed on the skin. With each heart beat, an electrical impulse or wave travels through the heart, which in turn, causes the heart muscles to pump blood from the heart to the rest of the body. The ECG records the voltage difference between pairs of electrodes and displays the rhythm of the heart and weaknesses that may be present in different parts of the heart. 
     In electrocardiography, a “lead” refers to a pair of electrodes that form an imaginary line in a patient along which electrical signals are measured. Three external leads, known as limb leads, form the three legs of what is known in the art as Einthoven&#39;s triangle. Einthoven&#39;s triangle defines an imaginary equilateral triangle having the heart at its center. Lead I is defined by a vector extending from a negative electrode on the right arm to a positive electrode on the left arm. Lead II is defined by a vector extending from the negative electrode on the right arm to a positive electrode on the left leg. Lead III is defined by a vector extending from a negative electrode on the left arm to the positive electrode on the left leg. 
     Current implantable cardiac rhythm management devices typically detect cardiac electrical activity between electrodes in or around the heart and the pulse generator, or between two electrodes on the pulse generator. The Reveal® Plus by Medtronic is a subcutaneously implantable loop recorder that can measure and record ECG data. U.S. Pat. No. 5,313,953 by Yomtov et al. discloses an implantable cardiac monitor with a subcutaneous lead proximate the heart, which is designed to process ECG signals. Additionally, prior art pacemaker and defibrillator manufacturers use associated cardiac leads connected to a sense amplifier in implantable pulse generators to facilitate ECG inputs. 
     Prior art implantable therapy devices such as pacemakers, defibrillators, and other devices have also been used to monitor thoracic impedance to detect respiration-related conditions, such as “lung water” and minute ventilation. This has been accomplished with the use of typically a single electrode implanted within the thoracic cavity, and an implantable pulse generator. While these implantable transthoracic methods of monitoring respiration were sometimes sufficient for diagnostic purposes, their single vector measurement approach leaves room for improvement for monitoring respiration for the purpose of timing the delivery of a therapy. 
     Significantly, however, cardiac electrical activity occurs over multiple electrical planes and vectors. Typically, approaches used by the prior art to monitor cardiac electrical activity lack complete information because they only detect electrical activity along one vector, such as between an electrode on a cardiac lead and the pulse generator. Furthermore, the prior art does not permit monitoring multiple ECG leads with an implantable medical device and integrating multiple-lead ECG information by an implantable medical device. 
     Thus, there remains a need in the art to be able to monitor cardiac electrical activity with an implantable medical device that can detect the ECG along at least three vectors, providing more complete information about heart function than existing devices and permitting discrimination of pathological events that cannot be detected with single-vector devices. Additionally, there exists a need in the art for a method for measuring ECGs and analyzing cardiac output that is also capable of detecting a patient&#39;s rate of respiration. 
     SUMMARY OF THE INVENTION 
     Improved methods for obtaining physiological parameters of a patient in accordance with various embodiments of the present invention can be used to monitor patient status and/or in conjunction with patient therapy. Physiological parameters can be monitored with an implantable device including a first lead and a second lead. In one embodiment, the first lead is implanted on the left carotid sinus and the second lead is implanted on the right carotid sinus. Physiological parameters can be measured along at least three distinct vectors defined by a first lead electrode and a second lead electrode, the first lead electrode and an electrode located on the device body, and the second lead an the electrode. Measurement across at least three vectors provides a more complete and accurate reading of patient physiological parameters than measurement across a single vector. An output indicative of the physiological parameter can then be provided. Therapy, such as baroreflex therapy, can optionally be optimized based on the physiological measurements. 
     In one embodiment, physiological parameters of a patient are monitored with an implantable monitoring system. Monitoring system can include a monitoring device operably connected to a first lead and a second lead. At least one physiological parameter of the patient can be measured by system along at least three distinct vectors. The first vector can be defined by an electrode on the first lead and an electrode on the second lead, the second vector by the electrode on the first lead and an electrode integrated into the monitoring device and the third vector by the electrode on the second lead and the electrode of the monitoring device. An output indicative of the physiological parameter can be provided to the care giver. In one embodiment, the measured parameter is voltage and the output is an ECG of the voltage. In another embodiment, the parameter is impedance and the output represents the patient&#39;s respiration. In a further embodiment, an output of the patient&#39;s respiration can be provided based on voltage measurements. 
     In another embodiment, baroreflex therapy can be optimized based on measurements of physiological parameters of a patient. A baroreflex device having an implantable pulse generator operably coupled to a first lead and a second lead can be implanted into the patient. The device can be used to measure at least one physiological parameter of the patient across at least three distinct vectors. The first vector can be defined by the first lead and the second lead, the second vector by the first lead and an electrode integrated into the monitoring device and the third vector by the second lead and the monitoring device. One or more baroreflex therapy pulses can be delivered through the first lead and second lead based on timing determined from the physiological parameter. In one embodiment, the physiological parameter is a voltage reported as an ECG reading, and the therapy pulses are configured to be delivered after a predetermined delay following an R-wave in the ECG. In another embodiment, the physiological parameter is impedance, which is used to determine the patient&#39;s respiration cycle, and therapy pulses are delivered during an expiration phase of the patient&#39;s respiration. In a further embodiment, both the patient&#39;s ECG and respiration are determined and therapy pulses are delivered after a predetermined delay following an R-wave that occurs during an expiration phase of the patient&#39;s respiration. 
     In one embodiment, a method of monitoring physiological cycles of a patient is provided. The method comprises implanting a monitoring system into the patient, the system including an implantable pulse generator operably connected to a lead, wherein the lead is implanted on a carotid sinus of the patient. The method further comprises measuring at least one signal indicative of a physiological parameter of the patient along at least two vectors selected from the group consisting of the following: a first vector defined between a first electrode of the lead and a second electrode of the lead, a second vector defined between the first electrode of the lead and an electrode integrated into an implantable pulse generator, and a third vector defined between the second electrode of the lead and the electrode integrated into the implantable pulse generator. The method further comprises providing an output indicative of the at least one signal indicative of the physiological parameter. 
     In another embodiment, a method comprises causing a monitoring system to be manufactured and made available to a user, the monitoring system including an implantable pulse generator operably connected to a lead, and providing instructions to the user, the instructions recorded on a tangible medium. The instructions comprise implanting the monitoring system into the patient such that the lead is implanted on a carotid sinus of the patient, measuring at least one signal indicative of a physiological parameter of the patient along at least two vectors selected from the group consisting of the following: a first vector defined between a first electrode of the lead and a second electrode of the lead, a second vector defined between the first electrode of the lead and an electrode integrated into an implantable pulse generator, and a third vector defined between the second electrode of the lead and the electrode integrated into the implantable pulse generator, and providing an output indicative of the at least one signal indicative of the physiological parameter. 
     It should be understood that the intention is not to limit the present invention to any particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the present invention as defined by the appended claims. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
       This invention may be more completely understood in consideration of the following detailed description of various embodiments of the invention in connection with the accompanying drawings, in which: 
         FIG. 1  is a schematic illustration of the upper torso of a human body showing the major arteries and veins and associated anatomy. 
         FIG. 2  is a cross-sectional schematic illustration of the autonomic nervous system. 
         FIG. 3  is a simplified schematic view of a baroreflex therapy device according to an embodiment of the present invention implanted in a patient. 
         FIG. 4  is a schematic diagram of a baroreflex modulation therapy system according to an embodiment of the present invention. 
         FIG. 5  is a graph illustrating a relationship between arterial blood pressure and autonomic nervous system activity. 
         FIG. 6  is a graph illustrating a method of baroreflex modulation therapy according to an embodiment of the present invention. 
         FIG. 7  is a graph illustrating a relationship between respiration, parasympathetic nervous system activity and sympathetic nervous system activity. 
         FIG. 8  is a graph illustrating a method of baroreflex modulation therapy according to an embodiment of the present invention. 
         FIG. 9  is a schematic diagram of a baroreflex modulation therapy system according to an embodiment of the present invention. 
         FIG. 10  is a graph illustrating a method of baroreflex modulation therapy according to an embodiment of the present invention. 
         FIG. 11  is a simplified schematic view of a baroreflex therapy device according to an embodiment of the present invention implanted in a patient. 
     
    
    
     While the invention is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention. 
     DETAILED DESCRIPTION OF THE DRAWINGS 
     The following detailed description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the invention. 
     To better understand the present invention, it may be useful to explain some of the basic vascular anatomy associated with the cardiovascular system. Refer to  FIG. 1  which is a schematic illustration of the upper torso of a human body  10  showing some of the major arteries and veins of the cardiovascular system. The left ventricle of the heart  11  pumps oxygenated blood up into the aortic arch  12 . The right subclavian artery  13 , the right common carotid artery  14 , the left common carotid artery  15 , and the left subclavian artery  15  branch off the aortic arch  12  proximal of the descending thoracic aorta  17 . Although relatively short, a distinct vascular segment referred to as the brachiocephalic artery  22  connects the right subclavian artery  13  and the right common carotid artery  14  to the aortic arch  12 . The right carotid artery  14  bifurcates into the right external carotid artery  18  and the right internal carotid artery  19  at the right carotid sinus  20 . Although not shown for purposes of clarity only, the left carotid artery  15  similarly bifurcates into the left external carotid artery and the left internal carotid artery at the left carotid sinus. 
     From the aortic arch  12 , oxygenated blood flows into the carotid arteries  18 / 19  and the subclavian arteries  13 / 16 . From the carotid arteries  18 / 19 , oxygenated blood circulates through the head and cerebral vasculature and oxygen depleted blood returns to the heart  11  by way of the jugular veins, of which only the right internal jugular vein  21  is shown for sake of clarity. From the subclavian arteries  13 / 16 , oxygenated blood circulates through the upper peripheral vasculature and oxygen depleted blood returns to the heart by way of the subclavian veins, of which only the right subclavian vein  23  is shown, also for sake of clarity. Deoxygenated blood from the upper torso and head eventually return to the heart  11  through the superior vena cava  23 . 1 , shown diagrammatically only. The heart  11  pumps the oxygen-depleted blood through the pulmonary system where it is re-oxygenated. The re-oxygenated blood returns to the heart  11  which pumps the re-oxygenated blood into the aortic arch as described above, and the cycle repeats. 
     Within the walls of many veins, the pulmonary vasculature and the chambers of the heart, as in the walls of the carotid sinus, aorta and other arterial structures, there are baroreceptors. Baroreceptors are a type of stretch receptor used by the body to sense blood pressure and blood volume. An increase in blood pressure or volume causes the vascular wall to stretch, and a decrease in blood pressure or volume causes the vascular wall to return to its original size. In many vessels, such a cycle is repeated with each beat of the heart. In others, in particular, some of the body&#39;s veins, the pressure and volume change more slowly. Because baroreceptors are located within the vascular wall, they are able to sense deformation of the adjacent tissue, which is indicative of a change in blood pressure or volume. 
     Refer now to  FIG. 2 , which shows a schematic illustration of the autonomic nervous system of a patient, including baroreceptors  30  disposed in a generic vascular wall  40  and a schematic flow chart of the baroreflex system  50 . Baroreceptors  30  are profusely distributed within the arterial walls  40  of the blood vessels and major arteries discussed previously, and are presently believed by the inventors to form an arbor  32  as is characteristic of the analogous receptors in the arterial system as described in commonly owned U.S. Pat. No. 6,522,926 to Kieval et al, which is incorporated herein by reference. A baroreceptor arbor  32  would comprise a plurality of baroreceptors  30 , each of which transmits baroreceptor signals to the brain  52  via nerve  38 . The baroreceptors  30  may be so profusely distributed and arborized within the vascular wall  40  that discrete baroreceptor arbors  32  are not readily discernable. To this end, those skilled in the art will appreciate that the baroreceptors  30  shown in  FIG. 2  are primarily schematic for purposes of illustration and discussion. In other regions, the baroreceptors may be so sparsely distributed that activation over a relatively greater length of the vein would be required than would be with an artery where the receptors might be more concentrated. 
     Baroreceptor signals in the arterial vasculature are used to activate a number of body systems which collectively may be referred to as the baroreflex system  50 . For the purposes of the present invention, it will be assumed that the “receptors” in the venous and cardiopulmonary vasculature and heart chambers function analogously to the baroreceptors in the arterial vasculature, but such assumption is not intended to limit the present invention in any way. In particular, the methods described herein will function and achieve at least some of the stated therapeutic objectives regardless of the precise and actual mechanism responsible for the result. Moreover, the present invention may activate baroreceptors, mechanoreceptors, pressoreceptors, or any other venous heart, or cardiopulmonary receptors which affect the blood pressure, nervous system activity, and neurohormonal activity in a manner analogous to baroreceptors in the arterial vasculature. For convenience, all such venous receptors will be referred to collectively herein as “baroreceptors.” Thus for discussion purposes, it will be assumed that baroreceptors  30  are connected to the brain  52  via the nervous system  51 . Thus, the brain  52  is able to detect changes in blood pressure which are indicative of cardiac output and/or blood volume. If cardiac output and/or blood volume are insufficient to meet demand (i.e., the heart  11  is unable to pump sufficient blood), the baroreflex system  50  activates a number of body systems, including the heart  11 , kidneys  53 , vessels  54 , and other organs/tissues. Such activation of the baroreflex system  50  generally corresponds to an increase in neurohormonal activity. Specifically, the baroreflex system  50  initiates a neurohormonal sequence that signals the heart  11  to increase heart rate and increase contraction force in order to increase cardiac output, signals the kidneys  53  to increase blood volume by retaining sodium and water, and signals the vessels  54  to constrict to elevate blood pressure. The cardiac, renal and vascular responses increase blood pressure and cardiac output  55 , and thus increase the workload of the heart  11 . In a patient with heart failure, this further accelerates myocardial damage and exacerbates the heart failure state. 
     The autonomic nervous system includes a sympathetic component and a parasympathetic component. The body uses these two systems to regulate blood pressure. The parasympathetic nervous system has a complementary relationship with the sympathetic nervous system. Stimulation of the parasympathetic nervous system generally causes a decrease in blood pressure, whereas stimulation of the sympathetic nervous system generally causes blood pressure to increase. 
     Baroreflex modulation therapy systems are used to treat patients with resistant hypertension by activating or modulating baroreceptors or other tissues capable of creating a change in the baroreflex system. Examples of such systems include The RHEOS System by CVRx, and the devices, systems, and methods described in U.S. Pat. Nos. 6,522,926, 6,985,774, 7,158,832, 7,480,532, and 7,840,271 and Published U.S. Patent Application Nos. 2006/0004417, 2006/0074453 and 2006/0293712, all of which are hereby incorporated by reference and are commonly assigned to the assignee of the present application. 
     In one embodiment of the present invention depicted in  FIG. 3 , a baroreflex modulation therapy system  100  comprises two leads  102 ,  104 , each including an electrode assembly  108 , and an implantable pulse generator (IPG)  106 . Rather than being located within the thoracic cavity of a patient  60 , the leads  102 ,  104  are implanted outside the chest cavity, such as on or near the carotid sinus. IPG can be implanted on either side of the patient&#39;s chest. Each electrode assembly  108  can include an anode  110  and a cathode  112 . In one embodiment, one lead  102  is located on the left carotid sinus  62  or left carotid artery and the other lead  104  is located on the right carotid sinus  64  or right carotid artery. In other embodiments, leads  102 ,  104 , can be implanted in other areas of the body, such as, for example, the pulmonary artery. 
     Baroreflex modulation therapy system  100  is capable of collecting ECG information from the patient by measuring electrical potential or voltage differences between the various elements of the system  100 . The system can monitor electrical signals and measure potential differences sensed between the two leads  102 ,  104  as well as between either of the leads  102 ,  104  and an electrode integrated with the IPG  106 , such as on the housing or header portion of IPG  106 . For each lead  102 ,  104 , either the anode  110  or cathode wire  112  can be used. 
     The lead  102 —lead  104  vector  120  replicates Lead I of Einthoven&#39;s Triangle. The right lead  104 —IPG  106  vector  122  replicates Lead II, and the left lead  102 —IPG  106  replicates Lead III. With this arrangement, system can detect ECG information along at least three vectors. Because a single vector is not likely to provide a complete picture of the electrical activity in the heart, measuring across multiple vectors, by measuring potential differences between various elements, is advantageous.  FIG. 4  depicts a block diagram further illustrating baroreflex modulation therapy system  100 . System  100  can include ECG measuring circuitry  130  configured to obtain ECG measurements through a combination of leads  102 ,  104  and IPG  106 . System  100  can also include a therapy circuit  132  for delivering therapeutic pulses through leads  102 ,  104 . A processor  134  can control the application of ECG measuring circuitry  130  and therapy circuit  134 . The configuration of anode  110  and cathode  112  are for illustrative purposes and should not be considered limiting. 
     ECG information obtained by baroreflex therapy system  100  can be used to provide diagnostic information to the physician regarding the cardiac rhythm status and/or to guide the timing and delivery of therapy by system  100 . In one embodiment, the baroreflex modulation therapy system is capable of recording, storing, and/or transmitting cardiac ECG information for future access by caregivers or the patient. As described herein, delivery of therapy pulses by baroreflex modulation therapy system can be more effective and use less energy if delivered at times when the body is experiencing increased baroreflex signaling. These times of increased baroreflex modulation can be determined from the ECG information. In other embodiments, other implantable devices, such as, for example, pacemakers and implantable defibrillators, can be configured as described above to obtain patient physiological parameters along at least three vectors. Such information can then be used diagnostically and/or to optimize therapy provided by the devices. 
     Referring to  FIG. 5 , an arterial blood pressure waveform  70  and a symbolic plot of autonomic nervous system activity  72  illustrate the relationship between arterial blood pressure and autonomic nervous system activity. The vertical lines  74  in the plot of autonomic nervous system activity represent the firing of baroreceptors that affect the parasympathetic and sympathetic components of the autonomic nervous system. As can be seen in the Figure, the firing of baroreceptors increases when a wave of increasing arterial pressure passes. Each pulse of increased pressure  76  in  FIG. 5  generally follows a corresponding contraction of the heart. 
       FIG. 6  depicts a diagram illustrating the operation of a baroreflex modulation therapy system according to one embodiment of the present invention. The diagram depicts a waveform  70  of a patient&#39;s arterial blood pressure and a waveform  78  of an ECG reading from the patient. 
     ECG reading can be obtained by measuring across at least three vectors utilizing a pair of leads and an IPG as described above. ECG waveform  78  includes a series of generally triangular-shaped R-waves  80 . Each R-wave  80  is associated with the electrical activation of the ventricles associated with a single heart beat. By comparing the arterial pressure waveform  70  and the ECG waveform  78 , it can be seen that each pulse of increased blood pressure  76  follows a corresponding contraction of the patient&#39;s heart, after a short delay. Each pulse of increased blood pressure  76  is expected to cause increased baroreflex activation in the patient. The diagram also depicts a baroreflex modulation therapy system control signal  82 . The control signal  82  indicates when baroreflex modulation therapy is enabled  84  and where it is disabled  86 . 
     In one embodiment, as shown in  FIG. 6 , there can be a time delay between the peak of each R-wave  80  and the delivery of a baroreflex therapy pulse  84 . The magnitude of the time delay may be pre-selected to correspond with a selected phase of the cardiac cycle. Delivering the therapy pulses slightly after the detection of an R-wave during the systolic phase of the cardiac cycle causes the therapy to be delivered as a relatively high level of pressure passes through the patient&#39;s arterial system, and, accordingly, as the body is experiencing increased baroreflex modulation. Delivery of therapy pulses during this time therefore complements the natural autonomic nervous activity of the body. Timing delivery of therapy in this manner can allow baroreflex modulation therapy to achieve the same level of therapeutic effect with less energy. This can extend the battery life and may enable the use of smaller baroreflex modulation therapy devices than would otherwise be necessary. In one embodiment, baroreflex modulation therapy device can auto-adjust therapy in response to the sensed physiological information. 
     Baroreflex modulation therapy can also take advantage of a relationship between respiration and autonomic nervous system activity. The efficacy of baroreflex modulation therapy may be influenced by when therapy is delivered relative to the respiratory cycle. Changes in respiration during and resulting from baroreflex modulation therapy may also provide important clinical information, including the rate of respiration, the depth of respiration, and the phases of respiration (inspiration versus expiration) using a combination of extra-thoracic electrodes and the implantable pulse generator. 
       FIG. 7  depicts a graph illustrating a relationship between respiration, sympathetic nervous system activity and parasympathetic nervous system activity. Respiration is represented by a tidal volume waveform  170  covering a number of respiratory cycles, each including an inspiration phase  172  and an expiration phase  174 . As can be seen in the Figures, parasympathetic nervous system activity  176  is generally elevated during the expiratory phase of the respiratory cycle, while sympathetic nervous activity  178  tends to peak during the inspiratory phase. Thus, in one embodiment shown in  FIG. 8 , baroreflex therapy pulses  184  can be delivered during the expiration phase in order to complement the natural parasympathetic nervous system activity of the body. This can allow the baroreflex modulation therapy device to achieve the same level of therapeutic effect while using less energy. 
     In one embodiment, a baroreflex therapy system  100  configured to delivery therapy in accordance with the respiration cycle of a patient can have respiration monitoring circuitry  136  as shown in  FIG. 9 . Respiratory monitoring circuitry  136  can be used with leads  102 ,  104  and IPG  106  to monitor, for example, impedance changes in the body of the patient that are indicative of respiratory activity. Impedance patterns change during respiration as air enters and leaves the thoracic cavity (lungs) during inspiration and expiration. In one embodiment, leads  102 ,  104  are implanted into the left carotid sinus and right carotid sinus, respectively. Respiratory monitoring circuitry  136  may work in cooperation with a constant current source  138  to monitor impedance across at least three vectors using leads  102 ,  104  and IPG  106 . Alternatively, system can have only ECG measuring circuitry  130  and no distinct respiration monitoring circuitry  136 . In such an embodiment, a patient&#39;s respiration cycle can be determined from the ECG measurements, as is known in the art. 
     Referring now to  FIG. 10 , baroreflex modulation therapy can be provided to take advantage of both the relationship between respiration and autonomic nervous system activity and the relationship between cardiac activity and autonomic nervous system activity. In the embodiment depicted in  FIG. 10 , therapeutic pulses  84  are delivered during the expiration phase  174  of respiration and shortly after the R-wave  80  during the systolic phase of each cardiac cycle. This provides therapeutic pulses in concert with both the cardiac and respiratory cycles, as described above. This can provide an even further reduction in the energy needed to provide effective therapy. 
     In another embodiment, the effectiveness of a given therapy may be evaluated by monitoring one or more physiologic parameters of a patient based on an impedance measurement taken across at least three vectors. The delivered therapy may comprise a cardiac rhythm management (CRM) therapy. In such an embodiment, an implantable pulse generator is provided, having at least two leads. A first lead is implanted and configured to deliver a CRM therapy. A second lead is coupled to a monitoring device according to one aspect of the present invention, the monitoring device having one or more electrodes and configured to measure impedance. The monitoring device may be disposed intravascularly, extravascularly, or transvascularly, depending on the desired application. The measured vascular impedance is used to provide one or more patient parameters, upon which the CRM therapy may be adjusted or modified. Other delivered therapies may include neural stimulation and/or modulation therapies, renal therapies, drug delivery therapies, left ventricular assist devices, heart wraps, other mechanical therapies, thermal therapies, or any other therapy having a measurement component in addition to a therapy component. 
     In another embodiment depicted in  FIG. 11 , additional measurement vectors can be utilized for patient that has another implantable device, such as a pacemaker  150  having a lead  152  inserted into the heart  11 , in addition to a baroreflex device having an IPG  106  and first  102  and second  104  leads. Thus in addition to measurement vectors  120 ,  122  and  124  between the IPG  106  and its two leads  102 ,  104 , there can be at least six additional measurement vectors, including two vectors  154 ,  156  between the IPG  106  and the pacemaker  150  and the IPG  106  and the lead  152  and four vectors  158 ,  160 ,  162 , and  164  between each lead  102 ,  104  and the pacemaker  150  and each lead  102 ,  104  and the pacemaker lead  152 . This can allow for even more precise readings of patient physical parameters. 
     In a related embodiment, IPG  106  may be configured to provide not only baroreflex therapy, but also CRM therapy such as pacing. IPG  106  therefore includes not only first lead  102  and second lead  104 , but also one or more cardiac leads  152 . In such an embodiment, additional measurement vectors exist between IPG  106  and cardiac lead  152 , lead  102  and cardiac lead  152 , and lead  104  and cardiac lead  152 . 
     In one embodiment, instructions for implanting the system in accordance with the various embodiments described herein in the form of printed or electronically, optically or magnetically stored information to be displayed, for example, are provided as part of a kit or assemblage of items prior to surgical implantation of the system. In another embodiment, instructions for implanting the system  10  in accordance with the various embodiments described herein are provided, for example, by a manufacturer or supplier of system, separately from providing the system, such as by way of information that is accessible using the Internet or by way of seminars, lectures, training sessions or the like. 
     The embodiments above are intended to be illustrative and not limiting. Additional embodiments are within the claims. In addition, although the present invention has been described with reference to particular embodiments, those skilled in the art will recognize that changes can be made in form and detail without departing from the spirit and scope of the invention. Any incorporation by reference of documents above is limited such that no subject matter is incorporated that is contrary to the explicit disclosure herein. 
     For purposes of interpreting the claims for the present invention, it is expressly intended that the provisions of Section 112, sixth paragraph of 35 U.S.C. are not to be invoked unless the specific terms “means for” or “step for” are recited in a claim.